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Rationale: Two forms of the IFN- release assay (IFNGRA) to detect
tuberculosis infection are available, but neither has been evaluated
in comparable HIV-infected and uninfected persons in a high tuber-
culosis incidence environment.
Objective:TocomparetheabilityoftheT-SPOT.TB(OxfordImmuno-
tec, Abingdon, UK), QuantiFERON-TB Gold (Cellestis, Melbourne,
Australia), and Mantoux tests to identify latent tuberculosis in HIV-
infected and uninfected persons.
Methods:Across-sectionalstudyof160healthyadultswithoutactive
tuberculosis attending a voluntary counseling and testing center
for HIV infection in Khayelitsha, a deprived urban South African
community with an HIV antenatal seroprevalence of 33% and a
tuberculosis incidence of 1,612 per 100,000.
Measurements and Main Results: One hundred and sixty (74 HIV
and 86 HIV
–)persons were enrolled. A lowerproportion of Mantoux
results was positive in HIV-infected subjects compared with HIV-
uninfected subjects (p  0.01). By contrast, the proportion of posi-
tive IFNGRAs was not significantly different in HIV-infected persons
for the T-SPOT.TB test (52 vs. 59%; p  0.41) or the QuantiFERON-
TB Gold test (43 and 46%; p  0.89). Fair agreement between the
Mantoux test (5- and 10-mm cutoffs) and the IFNGRA was seen in
HIV-infected people (  0.52–0.6). By contrast, poor agreement
between the Mantoux and QuantiFERON-TB Gold tests was ob-
served in the HIV-uninfected group (  0.07–0.30, depending on
the Mantoux cutoff). The pattern was similar for T-SPOT.TB ( 
0.18–0.24).
Interpretation: IFNGRA sensitivity appears relatively unimpaired by
moderately advanced HIV infection. However, agreement between
the tests and with the Mantoux test varied from poor to fair. This
highlights the need for prospective studies to determine which test
may predict the subsequent risk of tuberculosis.
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Tuberculosis infection may be accurately diagnosed by
IFN- release assay. However, these tests have not been
rigorously evaluated in settings where there is a high preva-
lence of HIV infection and high incidence of tuberculosis.
What This Study Adds to the Field
IFN-releaseassaysensitivityappearsrelativelyunaffected
by moderately advanced HIV infection. However, agree-
ment between the tests and with the Mantoux test varied
from poor to fair.
The World Health Organization has called for “urgent and ex-
traordinary actions” to control tuberculosis in Africa (1). Africa
contains 9 of the 22 countries with the highest tuberculosis bur-
den in the world, and the predominant factor driving the in-
creasedincidence oftuberculosis inthese areas is the high preva-
lence of HIV (2).
Detection of latent or recent infection, which represents the
reservoiroffuture tuberculosis cases,is an opportunityforinten-
siﬁedcontrol(3).InHIV-infectedpeoplewithlatenttuberculosis
infection(LTBI),isoniazidpreventivetherapy(IPT)isanunder-
utilized public health strategy (4). However, the skin reaction
to tuberculin PPD is impaired by HIV infection (5, 6). Further-
more, the tuberculin skin test (TST) has poor speciﬁcity in areas
of high bacillus Calmette-Gue ´rin (BCG) coverage and where
there is high prevalence of environmental mycobacteria (7). The
introductionofIFN- release assays (IFNGRAs)using immuno-
genic and speciﬁc Mycobacterium tuberculosis antigens (early
secretory antigenic target [ESAT]-6 and culture ﬁltrate protein
10 kD [CFP-10]) for immunodiagnosis is therefore a potential
advance. Compared with the TST,research using IFNGRA indi-
cates a high sensitivity for active tuberculosis (8–10). Positive
scores in these assays have also been shown in contact studies
to equate well with a history of exposure to tuberculosis (11–13).
Two commercial forms of the IFNGRA are now variously
licensedforuseinthedevelopedworld:theT-SPOT.TB(Oxford
Immunotec, Abingdon, UK), which is based on the enzyme-
linked immunospot (ELISpot) assay (14); and the whole blood–
based QuantiFERON-TB Gold (QFT-G; Cellestis, Melbourne,
Australia), which uses an ELISA to detect IFN- released into
culture supernatant (15). Most data that supported licensing and
introduction of these tests were obtained from studies in regionsRangaka, Wilkinson, Seldon, et al.: HIV and Detection of Tuberculosis 515
of the world where tuberculosis is uncommon and with emphasis
on HIV-uninfected persons. Preliminary doubt that these assays
can be applied to HIV-infected people has been raised (16, 17)
although ELISpot-based analyses report encouraging sensitivity
(73–90%) for active HIV-associated tuberculosis in both chil-
dren and adults (18, 19). There have been relatively few pub-
lished three-way comparisons of these tests (20–22), and no
study has systematically assessed the decrement in sensitivity
that might be conferred by HIV infection in comparable HIV-
infected and uninfected persons. Further, studies in developing
country environments are few. Some of the results of this study
have been previously reported in the form of an abstract (23).
METHODS
For additional detail on methods, see the online supplement.
Study Setting
The study was conducted in Khayelitsha, South Africa, at an integrated
tuberculosis/HIVclinicrunbyprovincialandcityhealthadministrations
together with Me ´decins sans Frontie `res (Geneva, Switzerland) (24).
Khayelitsha has an incidence of tuberculosis of 1,612 per 100,000 and
HIV infection is associated with a 36% per annum risk of developing
active tuberculosis. Seventy-six percent of tuberculosis is HIV associ-
ated and the prevalence of HIV infection in women attending antenatal
care is 33% (provincial and city data, 2005).
Recruitment and Selection
This study was approved by the University of Cape Town Research
Ethics Committee (REC 443/2004). Adults resident in Khayelitsha and
attending voluntary testing and counseling for HIV infection were in-
vited toparticipate.Personstestingseronegative forHIV-1 wereinvited
to participate after voluntary testing and counseling, on the day of their
negative test. Recruitment of persons found to be HIV seropositive
was deferred until their ﬁrst visit to the HIV/AIDS clinic, because we
did not wish to recruit them before they had time to accept their HIV
diagnosis. Prior tuberculosis, IPT, steroid therapy, pregnancy, and (in
HIV-infected people) a Karnofsky score not exceeding 60 or current
opportunistic infection were exclusions.
Clinical Assessment
Assessment of eligibility included a symptom-screening questionnaire
and physical examination for active tuberculosis based on validated
approaches (25, 26). The presence of any one of the following—cough,
chest pain, recent weight loss, night sweats, fever, loss of appetite,
swelling of lymph nodes, generalized tiredness—formed an exclusion
Figure 1. Flow chart showing numbers re-
cruited in both HIV status groups and num-
bers obtained for final analysis. QFT-G 
QuantiFERON-TB Gold (commercial form of
IFN- release assay [IFNGRA] from Cellestis,
Melbourne, Australia); T-SPOT.TB (commer-
cialformofIFNGRAfromOxfordImmunotec,
Abingdon, UK); TST  tuberculin skin test.
criterion and triggered referral. At the ﬁrst study visit blood was taken
and the intradermal (Mantoux) skin test was performed by placing
tuberculin PPD RT23 2TU on the volar aspect of the forearm. On the
second study visit, the transverse diameter of the TST induration was
determined by the ballpoint pen and ruler method. HIV-infected per-
sons with Mantoux reactions of or exceeding 5 mm were offered IPT
according to South African national guidelines.
Laboratory Assays
Blood samples were processed within 4 hours of drawing. The
T-SPOT.TB and QFT-G assays were performed and interpreted ac-
cording to the manufacturer’s insert guidelines (T-SPOT.TB) and, in
the case of QFT-G, the latest update at the manufacturer’s website.
Laboratory staff were blind to the clinical status of samples. Scoring
was carried out by a third investigator who had no role in clinical
recruitment or in performing the laboratory assays. In HIV-infected
persons, the CD4 cell count was simultaneously determined: persons qua-
lifying for antiretroviral therapy (CD4 cell count less than 200/mm3
or World Health Organization clinical stage 4) were referred to the
antiretroviral clinic.
Data Analysis
Contingency analysis was by 2 test or Fisher exact test. McNemar
paired analysis was used to compare proportions between the three
tests. Mantel-Haentzel methods were used to explore the data before
regression methods were employed. Adjustments were made for base-
line factor(s) shown by univariate analysis to be signiﬁcantly associated
with either HIV status or any test. Logistic regression was used to
obtain adjusted odds ratios and the likelihood ratio test was used to
determineoverallsigniﬁcanceandtestfortrendforcategoricalvariables
with more than two categories. Diagnostic test comparability was as-
sessed by computing  statistics. Signiﬁcance was inferred for p  0.05.
RESULTS
Baseline Characteristics of Participants by HIV Status and
Relationship to Test Positivity
One hundred and sixty persons were recruited, of whom 74 were
HIV infected and 86 were HIV uninfected (Figure 1). Baseline
characteristicsweresimilarlydistributedinthetwogroupsexcept
for the proportion with deltoid scarring (Table 1). This was
present in 51% (36 of 71) of the HIV-infected group compared
with 71% (56 of 79) in the HIV-uninfected group (p  0.01).
Sixteen (10%) persons did not return for the TST reading,
seven in the HIV-infected group and nine in the HIV-uninfected
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TABLE 1. BASELINE CHARACTERISTICS OF YOUNG ADULTS
ATTENDING VOLUNTARY COUNSELING AND TESTING FOR
HIV-1 INFECTION IN KHAYELITSHA TOWNSHIP, SOUTH
AFRICA
HIV Infected HIV Uninfected
(n  74)( n  86) p Value
Sex, % (n)
Female 73 (54) 60 (52) 0.10
Age, yr
Mean (SD) 30 (6.37) 30 (9.08) 0.68
TB contact in last 6 mo, % (n)
Yes 12 (9/73) 21 (18/85) 0.14
Deltoid/BCG scarring seen, % (n)
Yes 51 (36/71) 71 (56/79) 0.01
CD4 cell count
Median (IQR) 392 (263–520)
 200/mm
3, % (n) 16 (10)
200–349/mm3, % (n) 27 (17)
350–499/mm
3, % (n) 30 (19)
 500/mm
3, % (n) 28 (18)
Definition of abbreviations: BCG  bacillus Calmette-Gue ´rin; IQR  interquartile
range; TB  tuberculosis.
A total of 160 adults were studied. Note: Numbers in parentheses indicate
absolute number in group, and for factors where some information was missing,
denominators are given.
couldnotbeperformedbecauseofinsufﬁcientsampletoperform
both assays. Seven QFT-G results were scored indeterminate:
ﬁve (7%) HIV infected and two HIV uninfected (2%) (Table 2).
These persons were not obviously different in terms of baseline
characteristics from the groups to which positive or negative
scores could be assigned. Overall, therefore, the T-SPOT.TB
(158of159)yieldedasigniﬁcantlyhigherproportionofinterpret-
able results than did the QFT-G (151 of 158; p  0.04) and the
TST (144 of 160; p  0.001).
We next analyzed potential risk factors for tuberculosis infec-
tion (Table 1) and related these to positivity in any test. No fac-
tor was consistently associated with positivity for all the tests in
either the HIV-infected group or the uninfected group. Deltoid
scarring, in particular, was not associated with either IFNGRA
or TST positivity at any cutoff level.
TABLE 2. PROPORTION OF TESTS POSITIVE BY HIV STATUS
HIV Infected (n  74) HIV Uninfected (n  86) p Value (
2)
TST, % (n)
5-mm cutoff
Negative 48 (32) 14 (11)
Positive 52 (35) 86 (66)  0.0001
10-mm cutoff
Negative 51 (34) 17 (13)
Positive 49 (33) 83 (64)  0.0001
15-mm cutoff
Negative 63 (42) 42 (32)
Positive 37 (25) 58 (45) 0.01
T-SPOT.TB, % (n)
Negative 47 (34) 41 (35)
Positive 52 (38) 59 (51) 0.41
Indeterminate 1 (1) 0
QuantiFERON-TB Gold, % (n)
Negative 50 (37) 51 (43)
Positive 43 (32) 46 (39) 0.89
Indeterminate 7 (5) 2 (2)
Definition of abbreviation: TST  tuberculin skin test.
Effect of HIV Infection on Proportion of Positive Results for
Each Test
The median TST diameter was 8 mm (range, 0–30 mm) in HIV-
infectedsubjectsand15mm(range,0–50mm)inHIV-uninfected
subjects (p  0.0001). The distribution of TST reactions in both
groups was bimodal, persons tending to be either TST negative
or strongly positive (Figure 2). A signiﬁcantly lower proportion
of TST results was positive in the HIV-infected group compared
with the HIV-uninfected group regardless of TST cutoff (p 	
0.01; Table 2). This was evident even after controlling for the
absence of deltoid scarring (likelihood ratio test, p  0.0001;
Table 3). By contrast, the proportion of IFNGRA tests positive
in the HIV-infected group was not signiﬁcantly lower for
T-SPOT.TB (52 vs. 59%; p  0.41), or for QFT-G (43 and 46%;
p  0.89).
McNemar’s paired comparisons of the proportion positive by
either IFNGRA or TST in both groups were also conducted. In
HIV-uninfected persons, the proportion positive by T-SPOT.TB
was signiﬁcantly lower than by TST at both 5- and 10-mm cutoffs
(p  0.001; Figure 3B), a difference that disappeared at the
15-mm TST cutoff (p  0.56). Similar results applied to QFT-G,
with a signiﬁcantly lower proportion of QFT-G results positive
when compared with the TST at cutoff levels of 5 and 10 mm
(p  0.001; Figure 3C) but not at 15 mm (p  0.24; Figure 3E).
In HIV-infected people, the proportion positive by T-SPOT.TB
and TST at cutoffs of 5 and 10 mm did not differ (exact p 
1.00 and 0.58, respectively). However, a signiﬁcantly greater
proportion of T-SPOT.TB results was positive when compared
with the TST at the 15-mm cutoff (p  0.01). For the QFT-G,
there was no statistically signiﬁcant difference in proportions
detectedbytheassayandTSTatanycutoffpoint.Whencompar-
ing the two forms of the IFNGRA within the HIV exposure
groups, there was a trend toward greater positivity in the
T-SPOT.TB assay in the HIV-uninfected group (59 vs. 46%,
p  0.07).
Stratification of Results in HIV-infected Persons by
CD4 Cell Count
As both IFNGRAs depend predominantly on the CD4 recogni-
tion of M. tuberculosis antigens (27), a variable that will affect
testperformanceintheHIV-infectedgroupistheabsoluteCD4
cell count. Data were therefore explored by stratiﬁcation byRangaka, Wilkinson, Seldon, et al.: HIV and Detection of Tuberculosis 517
Figure 2. Distribution of TST results in HIV-infected and uninfected per-
sons. The distribution of skin test reactions in both groups was bimodal,
persons tending to be either negative or strongly positive.
CD4 cell count:  350,  250, and  200/mm3. The proportion
identiﬁed as tuberculosis infected in the lower CD4 cell count
group was higher for T-SPOT.TB compared with QFT-G (strati-
ﬁcation at a CD4 cell count of 250/mm
3 is shown in Figure 4).
This was observed regardless of the cutoff point for CD4 cell
count. With T-SPOT.TB, 48% (25), 54% (13), and 44% (9) at
CD4 cell count  350,  250, and  200/mm
3, respectively,
were identiﬁed as positive and QFT-G identiﬁed 33% (24), 33%
(12), and 26%, respectively (Figure 4). Tests for trend were,
however, not statistically signiﬁcant. When including the HIV-
uninfected group for comparison, the proportion positive clearly
fell for the TST (p  0.001 for 5 and 10 mm, and p  0.053 for
15 mm) but remained relatively constant for both IFNGRAs (p 
nonsigniﬁcant, regardless of whether indeterminate results were
factored as negative; Figure 4).
Agreement between Tests
InthecombinedHIV-infectedandHIV-uninfectedgroups,over-
all test agreement was signiﬁcant but moderate with  values
ranging from 0.31 to 0.40 (Table 4). In HIV-infected persons
agreement between the TST and both forms of IFNGRA was
fair at the 5- and 10-mm TST cutoffs (0.52–0.6, p  0.001)
butonlymoderateatthe15-mmcutoff(0.31–0.49,p	0.006).
QFT-G and T-SPOT.TB were also in moderate agreement in
the HIV-infected group (0.37, p  0.0001). Overall, 69%
of HIV-infected people were scored positive by one or more
test.
TABLE 3. EFFECT OF HIV INFECTION ON SKIN TEST
POSITIVITY* ADJUSTED FOR BASELINE FACTORS
OR for HIV
Adjusted Factor Infection (95% CI)
† p Value p Value (LRT)
‡
No adjustment 0.2 (0.10–0.45)  0.0001 —
Deltoid scarring 0.2 (0.09–0.45)  0.0001 0.72
Female sex 0.2 (0.09–0.46)  0.0001 0.97
TB contact 0.21 (0.09–0.47)  0.0001 0.77
Definition of abbreviations:C I confidence interval; LRT  likelihood ratio test;
OR  odds ratio; TB  tuberculosis.
* 
 10 mm.
† OR estimated by logistic regression
‡ LRT p values for the simple model showing the association between HIV
infection and skin test positivity compared with the model in which a baseline
factorisadjusted.NonsignificantLRTpvaluesindicatethatthesimpler,unadjusted
model best explains the data.
Figure 3. Pair-wise analysis of test results in HIV-uninfected persons:
2  2 tables show concordant and discordant test results for the HIV-
uninfected group.
In contrast, generally poor agreement between the TST and
IFNGRA was observed in the HIV-uninfected group. In this
group  values for QFT-G against TST at cutoff levels of
5 and 10 mm were poor (0.07 and 0.12, p  0.19 and 0.08,
respectively); against the TST at a cutoff of 15 mm, agreement
was slightly better with 0.30 (p  0.004). Although the
T-SPOT.TB showed marginally better agreement (65%, p 	
0.04, 0.17 and 0.18 for 5 and 10 mm, respectively) with the
lower grades of TST, the pattern was similar with best (albeit
stillonly moderate topoor) agreementwith TST at15mm (64%,
0.24, p  0.02). Poor agreement was contributed to by
Figure 4. Proportion positive in each test stratified by HIV status and
CD4 cell count. Although the proportion scored positive in lower
CD4 cell count strata tended to be consistently higher for T-SPOT.TB
compared with QFT-G, this effect was not statistically significant for
any CD4 cell count cutoff. When including the HIV-uninfected group
for comparison, the proportion positive clearly fell for the TST (p 
0.001 for 5 and 10 mm, and p  0.053 for 15 mm) but remained
relatively constant for the IFNGRA (p  nonsignificant, regardless of
whether indeterminate results were factored as negative).518 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 175 2007
TABLE 4. AGREEMENT BETWEEN TUBERCULIN SKIN TEST AT VARIOUS CUTOFFS, T-SPOT.TB TEST, AND QuantiFERON-TB
GOLD TEST
Combined Groups HIV Infected HIV Uninfected
Agreement (%)  p Value Agreement (%)  p Value Agreement (%)  p Value
QFT-G vs. T-SPOT.TB 68 0.37  0.001 67 0.34 0.002 70 0.40  0.001
QFT-G vs. TST 5 mm 65 0.31  0.001 79 0.58  0.001 53 0.07 0.189
QFT-G vs. TST 10 mm 65 0.31  0.001 76 0.52  0.001 55 0.12 0.078
QFT-G vs. TST 15 mm 65 0.31  0.001 66 0.31 0.006 65 0.30 0.005
T-SPOT.TB vs. TST 5 mm 72 0.40  0.001 80 0.60  0.001 65 0.17 0.035
T-SPOT.TB vs. TST 10 mm 72 0.40  0.001 80 0.60  0.001 65 0.18 0.034
T-SPOT.TB vs. TST 15 mm 68 0.37  0.001 74 0.49  0.001 64 0.24 0.016
both IFNGRA– TST pairs and IFNGRA TST– pairs (Figures
3B–3E).
DISCUSSION
This is the ﬁrst study to compare three methods to ascertain
LTBI in comparable groups of HIV-infected and uninfected
young adults in an area where there is a high incidence of tuber-
culosis and prevalence of HIV. The results indicate a high preva-
lence ( 69%) of LTBI among HIV-infected young adults in
this township, a ﬁnding that is of considerable public health
signiﬁcance.
Instudies oftheTST,itisdesirable toascertainBCGvaccina-
tion status. However, we found an inconsistent variety of scars
in both the left and right deltoid regions. Some of these were
characteristic of variolation, others of percutaneous or intrader-
mal BCG, and yet others that could not be reliably classiﬁed.
The median age of persons enrolled to this study was 30 years.
In 1976 and 1981 the geographic Eastern Cape birthplace of
many participants in this study transiently became the “indepen-
dent” apartheid homelands of Transkei and Ciskei, respectively.
OtherswereborninwhatwasconsideredSouthAfrica.Itfollows
that childhood immunization procedures, if in place at all, were
variable indeed and it was not therefore possible for us to ascer-
tainBCGstatuswithconﬁdence.Deltoidscarringwasnotassoci-
ated with positivity for anytest of tuberculosis sensitization. Our
results are consistent with other studies in adults from endemic
countries that demonstrate no relationship between TST positi-
vity and the presence of a BCG scar (28, 29).
Although 90% of TST determinations could be made, the
proportion of IFNGRAs that yielded an interpretable result was
higher (95.6% for QFT-G and 99.4% for T-SPOT.TB). The
differenceinproportionwassigniﬁcantfortheT-SPOT.TBwhen
compared with both tests. Thus both forms of the IFNGRA are
robust in a developing country setting albeit in the context of
research conducted by experienced personnel. Even if the pa-
tient does not reattend for IFNGRA results the determination
will remain valid, which is not the case for the TST. One issue
that has arisen with the QFT-G test is postmarketing reﬁnement
of the manufacturer’s criteria of what constitutes an unaccept-
able “nil” (i.e., unstimulated blood) value for IFN- detected
by ELISA (9, 30). High nil values complicate the interpretation
of the antigen-stimulated increment, but in this study we found
a lower proportion of QFT-G assays indeterminate than in other
studies of immunocompromised patients (16, 20).
OurstudyshowedacleardecrementinTSTreactivityinHIV-
infected persons when compared with HIV-uninfected persons
from the same community. This is consistent with many previous
evaluations of the TST (31, 32). There was no similar HIV-
related decrement in response in the HIV-infected subjects
tested by IFNGRA. This highly encouraging ﬁnding therefore
suggests that the IFNGRA could better identify HIV-infected
persons at risk of tuberculosis. However, the median CD4 cell
count of our patients was relatively high at 392/mm
3 and there
was a trend toward decreased positivity for QFT-G in those with
counts less than 250/mm3 (Figure 4). It is also arguable that in
an area where the incidence of tuberculosis is 1,612 per 100,000,
a high proportion of positive IFNGRAs was expected and might
be expected to be higher still in the HIV-infected group, the
group most susceptible to tuberculosis. As there is no “gold
standard” for the diagnosis of latent tuberculosis infection, the
manufacturers of both forms of IFNGRA have pragmatically
based estimation of sensitivity on the detection frequency of
HIV-uninfected patients with active tuberculosis in developed
countries. Whether this is generalizable to sensitivity to detect
latent tuberculosis could be questioned. A correlation between
antigen load and the extent of IFN- secretion in response to
ESAT-6 and CFP-10 has been observed both in experimental
systems and in humans (33–35). Further evidence in favor of
this relationship comes from observations that demonstrate a
falling response during successful chemotherapeutic treatment
(3, 33, 36). The bacillary burden in LTBI is many logs lower
than in active disease and so it may not be possible to conclude
with conﬁdence that a negative IFNGRA excludes LTBI. In
this respect addition of further species-speciﬁc antigens to test
formulations might incrementally improve sensitivity (29, 37).
Cutoffs for novel diagnostic tests are often deﬁned by receiver
operator characteristic (ROC) analysis. However, inthe absence
of a gold standard to diagnose latent tuberculosis, the division
of our groups into affected and unaffected would have been
arbitrary. In addition, both IFNGRAs under investigation have
manufacturer-deﬁnedcutoffsthatthereforedeﬁnedouranalysis.
It would be possible to deﬁne ROC curves for these tests only by
comparingmicrobiologically conﬁrmedcaseswith similarpeople
who were deﬁnitely not latently infected. Even were the latter
possible to ascertain, the appropriateness of such ROC analysis
is questionable given the previously cited considerations.
Overall agreement between the TST and IFNGRAs tended
to be lower than has been reported in similar studies from lower
tuberculosisincidence environments (15). Ourresults areconsis-
tent with similar poor agreement in high-prevalence areas found
between generations of the QuantiFERON test and the TST in
a nearby area of South Africa (29), and with others made in
Korea (38). In the HIV-infected group, discordant pair compari-
sons of IFNGRA and TST at a cutoff of 5 mm or more suggest
that the sensitivities of the tests may be similar. At a higher
skin test cutoff, there were signiﬁcantly more positive IFNGRA
results with negative TST results. This may be interpreted as
higher sensitivity of IFNGRA for tuberculosis infection. By
contrast, in the HIV-uninfected group there were signiﬁcantly
more positive TST results that were not detected by IFNGRA,
resulting in poor agreement even at the 15-mm TST cutoffRangaka, Wilkinson, Seldon, et al.: HIV and Detection of Tuberculosis 519
(Figures 3D and 3E). Our analysis indicated such reactions are
unlikely to arise via BCG vaccination. Another possibility is the
existence of a strongly sensitizing environmental mycobacte-
rium: the better agreement between the TST and IFNGRA in
the HIV-infected group reﬂecting the inability of this group to
maintain such a response. The other alternative, as discussed
previously, is that the TST-positive, IFNGRA-negative re-
sponses reﬂect true sensitization by M. tuberculosis that is unde-
tected by the IFNGRA. In this respect the greater proportion of
positiveT-SPOT.TBresultsinbothHIV-infectedanduninfected
persons (Table 2 and Figure 3) accords with an analysis sug-
gesting greater sensitivity of this method when compared with
QFT-G (20).
Our data suggest that there may be a role for IFNGRA in
the context of high HIV/TB prevalence. However, it is clear
from our analysis of agreement that the information on immune
status provided by these tests differs substantially from the TST
and even between tests. Furthermore, in their current format,
both IFNGRAs still require relatively specialized laboratories
removed from the point of care and cost is another limiting
factor. It is our opinion that sensitivity to detect latent tubercu-
losis cannot be assigned and therefore meaningfully discussed
when the positive predictive value (i.e., of subsequent active
tuberculosis) is not known for either method. Despite the cost
and ethical difﬁculties that will need to be overcome, what is
neededarelargeprospectivestudiestodeterminewhethereither
ofthese methods more accurately predicts the riskof subsequent
active tuberculosis better than the TST.
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